Atrimustine
Alternative Names: Bestrabucil; Busramustine; KM 2210; KreganLatest Information Update: 09 Jan 1995
At a glance
- Originator Kureha Corporation
- Class Antineoplastics
- Mechanism of Action DNA inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Graft-versus-host disease; Non-Hodgkin's lymphoma
Most Recent Events
- 09 Jan 1995 Discontinued-Preclinical for Graft-versus-host disease in Japan (Unknown route)
- 07 Nov 1994 Discontinued-preregistration for Breast cancer in Japan (PO)
- 07 Nov 1994 Discontinued-preregistration for Non-Hodgkin's lymphoma in Japan (PO)